However, whole-exome sequencing techniques have now identified point mutations in the human synaptotagmin 2 (syt2) gene in patients with a disease combining congenital myasthenic syndrome and distal motor weakness, suggesting a role for synaptotagmin in neuromuscular disease [17, 18]. This evidence concerns the gene SYT2 and congenital myasthenic syndrome.